Document Type


Journal Title

Journal of child and adolescent psychopharmacology

Publication Date





OBJECTIVE: To collect pilot data assessing the safety, tolerability, and efficacy of tomoxetine, a nonstimulant norepinephrine enhancer, in pediatric attention deficit hyperactivity disorder (ADHD).

METHODS: An open-label trial of tomoxetine in pediatric ADHD was conducted as part of a multisite clinical trial. Following a baseline assessment, an ascending dose titration was completed during 10 weekly visits.

RESULTS: Ten subjects were enrolled at baseline, with eight completing the study. Seven of the eight remaining subjects met efficacy criteria. Significant decreases in symptom severity ratings by parents and study investigators were found. The medication was well tolerated, with transient appetite suppression the most frequently reported side effect. However, subjects' weights remained stable across study visits.

DISCUSSION: These preliminary findings suggest that tomoxetine may hold promise as a treatment for pediatric ADHD.

MeSH Headings

Adolescent, Antidepressive Agents, Attention Deficit Disorder with Hyperactivity, Child, Dose-Response Relationship, Drug, Humans, Male, Propylamines, Psychiatric Status Rating Scales




This is a copy of an article published in the Journal of child and adolescent psychopharmacology © 2001 copyright Mary Ann Liebert, Inc.; Journal of child and adolescent psychopharmacology is available online at:

Included in

Psychiatry Commons